Status:
RECRUITING
Efficacy and Safety of Fecal Microbiota Transplantation
Lead Sponsor:
Guangzhou First People's Hospital
Conditions:
Fecal Microbiota Transplantation
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
In recent years, researches illustrate that multifactorial diseases such as functional gastrointestinal disorders, autoimmune diseases, metabolic, behavioral and neurological diseases are associated w...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of any of following diseases:
- Irritable Bowel Syndrome
- Ulcerative colitis
- Crohn's disease
- Constipation
- Clostridium Difficile Infection
- Functional Dyspepsia
- Parkinson's Disease
- Metabolic Syndrome
- Non-Alcoholic Fatty Liver Disease
- Autism Spectrum Disorder
- Radiation Enteritis
- Atopic Dermatitis
- Food Allergic
- Graft-versus-Host Disease
- Obesity
- Diabetes mellitus
- Multi-Drug Resistant Infection
- Hepatic Encephalopathy
- Enteric Dysbacteriosis
- Multiple Sclerosis
- Pseudomembranous Enteritis
- Acute Pancreatitis
- Chronic Fatigue Syndrome
- Acute-on-chronic Liver Failure with HBV Infection
- Alcoholic Liver Disease
- Anorexia
- Decompensated Cirrhosis
- Henoch-Schonlein Purpura
- Autoimmune Liver Disease
- Systemic Lupus Erythematosus
- Rheumatoid arthritis
- IgG4-Related Disease
- Celiac Disease
- Protein-losing Enteropathy
- Asperger Syndrome
- Rheumatoid arthritis
- Psoriasis
- Ankylosing spondylitis
- Immune checkpoint inhibition-related colitis
- Autoimmune enteropathy
- Drug-induced diarrhea
- Suffering from gastrointestinal symptoms such as constipation, diarrheas, abdominal pain, flatulence, etc.
- The participants must be able to tolerate the FMT infusion method such as endoscopy, colonoscopy, capsule, nasoduodenal tube insertion, etc.
Exclusion
- Current pregnancy or breast-feeding;
- Suffering from other severe diseases, including liver or kidney failure, heart failure, MODS, coma, cerebrovascular accident;
- Known contraindication to all FMT infusion method such as nasoduodenal tube insertion, endoscopy, colonoscopy and enema;
- Any conditions that may render the efficacy of FMT or at the discretion of the investigators.
Key Trial Info
Start Date :
January 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04706611
Start Date
January 15 2021
End Date
December 31 2026
Last Update
April 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou First People's Hospital
Guangzhou, Guangdong, China, 510180